The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Vivimed Labs to clarify why segment-wise details were not submitted along with its financial results for the quarter ended 30 June 2025, as required under Regulation 33 of the SEBI Listing Regulations. The company has not yet responded to the exchange's query. This is a routine compliance clarification and not an enforcement or penalty action. Investors should wait for the company's official response to understand the reason for the omission.
This is a minor procedural matter and unlikely to move the stock price significantly. However, repeated or unresolved clarifications can flag weak compliance practices and may dent investor confidence in the company's disclosure standards.